The shadow of generic competition has repeatedly loomed over copyright’s blockbuster drug, Viagra, raising questions about the outlook of similar pharmaceutical portfolios. While first years saw impressive profits, the patent end has created the path for less expensive alternatives, possibly diminishing revenue and posing a significant danger for